Compare WDH & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WDH | CADL |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 596.7M | 578.8M |
| IPO Year | 2020 | 2021 |
| Metric | WDH | CADL |
|---|---|---|
| Price | $1.47 | $8.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 174.1K | ★ 2.2M |
| Earning Date | 06-04-2026 | 05-14-2026 |
| Dividend Yield | ★ 3.57% | N/A |
| EPS Growth | N/A | ★ 58.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.71 | N/A |
| P/E Ratio | $9.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.29 | $4.35 |
| 52 Week High | $2.18 | $9.27 |
| Indicator | WDH | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 39.31 | 68.29 |
| Support Level | $1.43 | $4.80 |
| Resistance Level | $1.74 | $9.27 |
| Average True Range (ATR) | 0.05 | 0.60 |
| MACD | -0.00 | -0.04 |
| Stochastic Oscillator | 22.22 | 75.28 |
Waterdrop Inc is a technology platform dedicated to insurance and healthcare service. The Company is mainly engaged in operating an independent third-party insurance platform dedicated to providing insurance and healthcare service. The Company's main businesses are the insurance marketplace, medical crowdfunding, and mutual aid. The insurance marketplace business is collaborated with insurance carriers to offer health and life insurance products to ensure a smooth and friendly user experience throughout the process from underwriting to claim services. The medical crowdfunding business enabled people with medical costs.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.